Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec;9(12):1058-1068.
doi: 10.1016/j.trecan.2023.08.011. Epub 2023 Sep 12.

Variant allele frequency: a decision-making tool in precision oncology?

Luca Boscolo Bielo  1 , Dario Trapani  1 , Matteo Repetto  2 , Edoardo Crimini  1 , Carmine Valenza  1 , Carmen Belli  3 , Carmen Criscitiello  1 , Antonio Marra  3 , Vivek Subbiah  4 , Giuseppe Curigliano  5
Affiliations
Review

Variant allele frequency: a decision-making tool in precision oncology?

Luca Boscolo Bielo et al. Trends Cancer. 2023 Dec.

Abstract

Precision oncology requires additional predictive biomarkers for targeted therapy selection. Variant allele frequency (VAF), measuring the proportion of variant alleles within a genomic locus, provides insights into tumor clonality in somatic genomic testing, yielding a strong rationale for targeting dominant cancer cell populations. The prognostic and predictive roles of VAF have been evaluated across different studies. Yet, the absence of validated VAF thresholds and a lack of standardization between sequencing assays currently hampers its clinical utility. Therefore, analytical and clinical validation must be further examined. This Review summarizes the evidence regarding the use of VAF as a predictive biomarker and discusses challenges and opportunities for its clinical implementation as a decision-making tool for targeted therapy selection.

Keywords: biomarker qualification; precision oncology; predictive biomarker; targeted therapy; variant allele frequency.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests MR received travel expenses reimbursement from Sanofi. CC reports personal fees for consulting, advisory role, and speakers’ bureau from Lilly, Roche, Novartis, MSD, Seagen, Gilead, and Pfizer. VS served consulting or advisory role for MedImmune, Helsinn Therapeutics, Relay Therapeutics, Pfizer, and Loxo/Lilly. Research funding: Novartis, GlaxoSmithKline, NanoCarrier, Northwest Biotherapeutics, Genentech/Roche, Berg Pharma, Bayer, Insyte, Fujifilm, PharmaMar, D3 Oncology Solutions, Pfizer, Amgen, AbbVie, Multivir, Blueprint Medicines, LOXO, Vegenics, Takeda, Alfasigma, Agensys, Idera, Boston Biomedical, Inhibrx, Exelixis, Turning Point Therapeutics, and Relay Therapeutics. Travel, accommodation, expenses: PharmaMar, Bayer, Novartis, Helsinn Therapeutics, and Foundation Medicine. Other relationships: Medscape. GC received honoraria for speaker's engagement: Roche, Seattle Genetics, Novartis, Lilly, Pfizer, Foundation Medicine, NanoString, Samsung, Celltrion, BMS, and MSD; Honoraria for providing consultancy: Roche, Seattle Genetics, and NanoString; Honoraria for participating in Advisory Board: Roche, Lilly, Pfizer, Foundation Medicine, Samsung, Celltrion, and Mylan; Honoraria for writing engagement: Novartis and BMS; Honoraria for participation in Ellipsis Scientific Affairs Group; Institutional research funding for conducting phase I and II clinical trials: Pfizer, Roche, Novartis, Sanofi, Celgene, Servier, Orion, AstraZeneca, Seattle Genetics, AbbVie, Tesaro, BMS, Merck Serono, Merck Sharp Dohme, Janssen-Cilag, Philogen, Bayer, Medivation, and Medimmune. The remaining authors have no conflict of interest to declare.

LinkOut - more resources